← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
CLNN
Clene Inc.
Valuation N/A
Healthcare Risk 62 · High
Price$3.57
Model IV—
P/IV—
Market implies +100.5%/yr vs model +2.0% · above model
CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE
Valuation N/A
Financial Services Risk 40 · Elevated
Price$4.82
Model IV—
P/IV—
Limited data — see page
CLPT
ClearPoint Neuro, Inc.
Valuation N/A
Healthcare Risk 57 · Elevated
Price$13.72
Model IV—
P/IV—
Market implies +45.5%/yr vs model +22.7% · above model
CLRB
Cellectar Biosciences, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$2.31
Model IV—
P/IV—
Limited data — see page
CLRO
CLEARONE INC
Valuation N/A
Technology Risk 45 · Elevated
Price$4.99
Model IV—
P/IV—
Market implies -18.3%/yr vs model +15.0% · below model
CLWT
EURO TECH HOLDINGS CO LTD
Valuation N/A
Industrials Risk 33 · Moderate
Price$1.58
Model IV—
P/IV—
Market implies +37.9%/yr vs model +2.0% · above model
CLYM
Climb Bio, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$14.25
Model IV—
P/IV—
Limited data — see page
CM
CANADIAN IMPERIAL BANK OF COMMERCE /CAN/
Valuation N/A
Financial Services Risk 33 · Moderate
Price$113.35
Model IV—
P/IV—
Limited data — see page
CMBT
CMB.TECH NV
Valuation N/A
Industrials Risk 26 · Moderate
Price$19.48
Model IV—
P/IV—
Limited data — see page
CMCL
Caledonia Mining Corp Plc
Valuation N/A
Basic Materials Risk 57 · Elevated
Price$25.70
Model IV—
P/IV—
Limited data — see page
CMCM
Cheetah Mobile Inc.
Valuation N/A
Technology Risk 54 · Elevated
Price$3.09
Model IV—
P/IV—
Market implies +50.2%/yr vs model +7.5% · above model
CMII
Columbus Circle Capital Corp II
Valuation N/A
Financial Services
Price$10.05
Model IV—
P/IV—
Limited data — see page
CMMB
Chemomab Therapeutics Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$2.58
Model IV—
P/IV—
Limited data — see page
CMND
Clearmind Medicine Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.97
Model IV—
P/IV—
Limited data — see page
CMPS
COMPASS Pathways plc
Valuation N/A
Healthcare Risk 31 · Moderate
Price$14.54
Model IV—
P/IV—
Limited data — see page
CMPX
Compass Therapeutics, Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$2.00
Model IV—
P/IV—
Market implies +82.9%/yr vs model +15.0% · above model
CMTG
Claros Mortgage Trust, Inc.
Valuation N/A
Real Estate Risk 67 · High
Price$1.49
Model IV—
P/IV—
Market implies +27.1%/yr vs model +2.0% · above model
CMU
MFS HIGH YIELD MUNICIPAL TRUST
Valuation N/A
Unknown
Price$3.73
Model IV—
P/IV—
Limited data — see page
CNCK
Coincheck Group N.V.
Valuation N/A
Financial Services Risk 55 · Elevated
Price$1.92
Model IV—
P/IV—
Limited data — see page
CNF
CNFinance Holdings Ltd.
Valuation N/A
Financial Services Risk 45 · Elevated
Price$1.95
Model IV—
P/IV—
Limited data — see page
CNI
CANADIAN NATIONAL RAILWAY CO
Valuation N/A
Industrials Risk 33 · Moderate
Price$122.09
Model IV—
P/IV—
Limited data — see page
CNL
Collective Mining Ltd.
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$12.87
Model IV—
P/IV—
Limited data — see page
CNQ
CANADIAN NATURAL RESOURCES LTD
Valuation N/A
Energy Risk 33 · Moderate
Price$50.32
Model IV—
P/IV—
Limited data — see page
CNS
COHEN & STEERS, INC.
Valuation N/A
Financial Services Risk 55 · Elevated
Price$72.34
Model IV—
P/IV—
Market implies +38.5%/yr vs model +2.0% · above model
CNSP
CNS Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$5.84
Model IV—
P/IV—
Limited data — see page
CNTA
Centessa Pharmaceuticals plc
Valuation N/A
Healthcare Risk 30 · Moderate
Price$40.50
Model IV—
P/IV—
Market implies +83.7%/yr vs model +15.0% · above model
CNTB
Connect Biopharma Holdings Ltd
Valuation N/A
Healthcare Risk 30 · Moderate
Price$2.04
Model IV—
P/IV—
Market implies +63.9%/yr vs model +15.0% · above model
CNTN
Canton Strategic Holdings, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$2.11
Model IV—
P/IV—
Limited data — see page
CNTX
Context Therapeutics Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.35
Model IV—
P/IV—
Limited data — see page
CNXU
Conexeu Sciences Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$4.46
Model IV—
P/IV—
Limited data — see page
COAG
Hemab Therapeutics Holdings, Inc.
Valuation N/A
Healthcare Risk 51 · Elevated
Price$39.40
Model IV—
P/IV—
Limited data — see page
COCH
Envoy Medical, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.74
Model IV—
P/IV—
Market implies +46.9%/yr vs model +15.0% · above model
COCP
Cocrystal Pharma, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$1.24
Model IV—
P/IV—
Limited data — see page
CODX
Co-Diagnostics, Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$1.12
Model IV—
P/IV—
Market implies +36.5%/yr vs model +2.0% · above model
COE
51Talk Online Education Group
Valuation N/A
Consumer Defensive Risk 42 · Elevated
Price$10.61
Model IV—
P/IV—
Market implies +16.1%/yr vs model +50.0% · below model
COF
CAPITAL ONE FINANCIAL CORP
Valuation N/A
Financial Services Risk 55 · Elevated
Price$208.30
Model IV—
P/IV—
Limited data — see page
COGT
Cogent Biosciences, Inc.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$33.41
Model IV—
P/IV—
Limited data — see page
COHR
COHERENT CORP.
Valuation N/A
Healthcare Risk 50 · Elevated
Price$266.50
Model IV—
P/IV—
Market implies +30.1%/yr vs model +17.0% · above model
COHU
COHU INC
Valuation N/A
Healthcare Risk 62 · High
Price$57.08
Model IV—
P/IV—
Market implies +36.6%/yr vs model +2.0% · above model
COKE
Coca-Cola Consolidated, Inc.
Valuation N/A
Consumer Defensive Risk 58 · Elevated
Price$192.61
Model IV—
P/IV—
Limited data — see page
COLA
Columbus Acquisition Corp/Cayman Islands
Valuation N/A
Financial Services Risk 26 · Moderate
Price$10.61
Model IV—
P/IV—
Limited data — see page
COLAR
Columbus Acquisition Corp/Cayman Islands
Valuation N/A
Financial Services Risk 42 · Elevated
Price$0.40
Model IV—
P/IV—
Limited data — see page
COOK
Traeger, Inc.
Valuation N/A
Technology Risk 72 · High
Price$49.20
Model IV—
P/IV—
Market implies +44.0%/yr vs model +2.0% · above model
COOT
Australian Oilseeds Holdings Ltd
Valuation N/A
Consumer Defensive Risk 43 · Elevated
Price$0.43
Model IV—
P/IV—
Limited data — see page
COPL
Copley Acquisition Corp
Valuation N/A
Financial Services
Price$10.54
Model IV—
P/IV—
Limited data — see page
CORN
Teucrium Commodity Trust
Valuation N/A
Financial Services Risk 40 · Elevated
Price$19.92
Model IV—
P/IV—
Limited data — see page
CORZ
Core Scientific, Inc./tx
Valuation N/A
Financial Services Risk 34 · Moderate
Price$16.04
Model IV—
P/IV—
Market implies +49.4%/yr vs model +2.0% · above model
CORZZ
Core Scientific, Inc./tx
Valuation N/A
Financial Services Risk 26 · Moderate
Price$17.59
Model IV—
P/IV—
Market implies +140.5%/yr vs model +2.0% · above model
COYA
Coya Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$4.38
Model IV—
P/IV—
Market implies +21.5%/yr vs model +15.0% · above model
CP
CANADIAN PACIFIC KANSAS CITY LTD/CN
Valuation N/A
Industrials Risk 33 · Moderate
Price$89.77
Model IV—
P/IV—
Limited data — see page
CPA
Copa Holdings, S.A.
Valuation N/A
Industrials Risk 36 · Moderate
Price$129.15
Model IV—
P/IV—
Limited data — see page
CPAC
CEMENTOS PACASMAYO SAA
Valuation N/A
Industrials Risk 37 · Moderate
Price$12.54
Model IV—
P/IV—
Limited data — see page
CPER
United States Commodity Index Funds Trust
Valuation N/A
Financial Services Risk 32 · Moderate
Price$38.26
Model IV—
P/IV—
Limited data — see page
CPHI
CHINA PHARMA HOLDINGS, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.76
Model IV—
P/IV—
Market implies -2.7%/yr vs model +2.0% · below model
CPSH
CPS TECHNOLOGIES CORP/DE/
Valuation N/A
Industrials Risk 40 · Elevated
Price$4.08
Model IV—
P/IV—
Market implies +17.0%/yr vs model +9.8% · above model
CPSS
CONSUMER PORTFOLIO SERVICES, INC.
Valuation N/A
Financial Services Risk 45 · Elevated
Price$9.43
Model IV—
P/IV—
Market implies -48.5%/yr vs model +13.1% · below model
CPZ
Calamos Long/Short Equity & Dynamic Income Trust
Valuation N/A
Unknown
Price$13.06
Model IV—
P/IV—
Limited data — see page
CRAC
Crown Reserve Acquisition Corp. I
Valuation N/A
Financial Services
Price$10.20
Model IV—
P/IV—
Limited data — see page
CRACR
Crown Reserve Acquisition Corp. I
Valuation N/A
Financial Services
Price$0.14
Model IV—
P/IV—
Limited data — see page
CRAN
Crane Harbor Acquisition Corp. II
Valuation N/A
Financial Services
Price$10.14
Model IV—
P/IV—
Limited data — see page